Figure 3.
Anti-Aβ antibodies fail to specifically promote plaque association or clearance by peripheral myeloid cells. (a) Representative images of Iba1 immunohistochemistry (blue) combined with pFTAA staining (green) are shown. (b) Stereological quantification of number of Iba1-positive cells (left; n = 5–6 per group) and quantification of Iba1-positive cell bodies per pFTAA area (right; n = 5–6 per group; ***, P = 0.0005). (c and e) Representative images of 4G8 immunohistochemistry (c) and Congo red staining (e). (a, c, and e) Bars, 100 µm. (d) Stereological quantification of the area covered by 4G8-positive plaques (top; **, P = 0.009) and number of 4G8-positive plaques (bottom; *, P = 0.02; n = 5–7 per group). (f) Stereological quantification of the number of Congo red–positive plaques (*, P = 0.02; n = 5–7 per group). (g) Amount of soluble and insoluble Aβ40 and Aβ42 and total Aβ40 and Aβ42 calculated from individual protein fractions (*, P = 0.04; measurements performed in duplicate from n = 5–7 biological replicates per group). (h) Representative image of Western blot analyses of APP, APPCTFβ, and APPCTFα in SDS-extracted brain fractions (APPct detection; left) and representative quantification of Western blots (right; result representative of six independent experiments). All data are represented as mean ± SEM.